Back to top

AstraZeneca Updates Phase 1 Acalabrutinib Data in Japan: What Investors Should Watch

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. AstraZeneca’s latest clinical update centers on a Phase 1 study of acalabr...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

AstraZeneca PLC (AZN)